The aim of this review is to highlight the recent advances (in the past 12 months) concerning circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in oncology.
INTRODUCTION
In the past two decades, the medical community has witnessed the rapid development of molecular oncology, with powerful molecular profiling tools enabling a detailed characterization of cancer. However, our knowledge of the molecular evolution of cancer has been limited by the lack of access to tumor tissue throughout disease progression. Liquid biopsies, including analysis of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), are a promising new avenue for real-time monitoring of tumor progression. CTCs have been widely investigated during the past decade, with numerous studies addressing their prognostic value and potential for tumor molecular profiling [1] [2] [3] . More recently, ctDNA proved to be associated with tumor burden [4] , and to be representative of the underlying tumor genome [5 patients provided level-one evidence that CTCs are associated with decreased progression-free survival (PFS) and overall survival (OS) [11] . Analysis of CTCs in 2026 patients with early breast cancer (eBC) also confirmed that CTC detection is associated with worse clinical outcomes in that setting [12] . However, in an inter-reader variability study, agreement for CTC definition between independent readers was lower in early compared to mBC setting, suggesting that continuous training and central review should be applied in clinical trials using CTC detection in eBC [43] . A score integrating CTC enumeration with estrogen receptor, HER2, BCL-2, and Ki67 expression was recently developed in estrogen receptor-positive mBC to predict endocrine resistance; its clinical validity will be prospectively evaluated in clinical trials (NCT01701050, NCT02137837) [44] .
In metastatic castrate-resistant prostate cancer, the prognostic value of CTCs was recently prospectively validated in two phase III randomized trials [33, 34] . In the S0421 trial, higher baseline CTC count ( five per 7.5 ml) and CTC count increase at day 21 where both were associated with reduced OS [33] . Likewise, CTC count at 12 weeks combined with lactate dehydrogenase (LDH) level fulfilled all of Prentice's criteria for OS surrogacy in the COU-AA-301 trial [34] .
A recent meta-analysis also confirmed the adverse prognostic value of CTCs in metastatic KEY POINTS Circulating tumor cells have been validated as a prognostic biomarker, with ongoing trials assessing the clinical utility of CTCs to guide treatment-related decision.
Emerging data highlight the potential of circulating tumor cells for tumor RNA, DNA, and protein expression profiling, as well as for drug sensitivity testing, but clinical validation of these models is needed.
Recognition of specific mutations on plasma circulating cell-free DNA allows sensitive and specific detection of circulating tumor DNA, allowing potential use as a biomarker.
Tumor molecular profiling on circulating tumor DNA has shown good correlation with the tumor mutational landscape and could potentially be tested as an alternative to tumor tissue in molecular screening programs.
For each CTC or ctDNA assay to be used in clinical practice, demonstration of analytical and clinical validity, and then clinical utility in a specific setting, is needed. [36, 37] No No [37, 38] Head and neck Yes (MMAIT) [41] No No [41, 42] mBC, metastatic breast cancer; mCRC, metastatic colorectal cancer; mCRPC, metastatic castrate-resistant prostate cancer; ?, unknown.
colorectal cancer (CRC) [16] . However, the prognostic impact of CTCs in early CRC is unclear. Although small studies demonstrated association between CTC count and relapse in the early setting [17, 18] , a prospective analysis of CTCs in a cohort of 472 stage III CRC patients did not show association between CTCs, measured after tumor resection and before adjuvant therapy, and outcomes [19] . Differences in timing for CTC count, as well as distinct populations, may explain these conflicting results.
Small studies also explored CTC prognostic value in other tumor types such as lung, melanoma, and esophagogastric cancer, also revealing association with adverse outcomes [20] [21] [22] [28] [29] [30] . Moreover, few meta-analyses provided new evidence supporting the adverse prognostic value of CTCs in pancreas, ovarian, and head and neck cancer [25, 26, 38, 39] .
The association between CTCs and poor prognosis triggered attempts to investigate CTC potential to guide treatment decision. The SWOG S0500 trial addressed the benefit of switching therapy preemptively in case of persistent CTCs after 21 days of first-line chemotherapy in mBC [10 & ]. One hundred and twenty-three patients were randomized to continue therapy or to change to an alternate chemotherapy. Although the presence of CTCs was associated with poor prognosis, the early switch strategy failed to improve outcomes. An explanation for these results may be the lack of an efficient alternative therapy. Many ongoing trials are addressing treatment decision based not only CTC enumeration but also on CTC protein expression ( Table 2 ).
CIRCULATING TUMOR CELLS BEYOND ENUMERATION
Characterization of CTCs could help provide a better insight on the biology underlying metastasis development. For example, emerging data suggest that CTCs sometimes circulate in clusters with or without stromal cells, and that these clusters are implicated in the process of cancer dissemination [45, 46] .
There is a growing interest in exploiting CTCs as tumor tissue source to analyze protein expression, RNA expression, and DNA mutations. In prostate cancer, expression of androgen-receptor splice variant 7 RNA (AR-V7) on CTCs proved to be associated with resistance to enzalutamide and abiraterone [47] . Studies in various cancers also demonstrated the feasibility to detect specific mutations such as KRAS, BRAF, EGFR, ROS1, PI3KCA, or TP53 mutations on CTCs [1, [48] [49] [50] [51] [52] [53] [54] [55] [56] . Moreover, the feasibility to perform comprehensive whole-exome sequencing on CTCs was recently demonstrated and provided evidence that CTC analysis could [60 & ] showed that in patients with SCLC, the molecular profile of CTCs corresponded to that of CTC-derived explants (CDX), and that CDX reflected patient's tumor response to platinumbased chemotherapy, providing a model to study drug resistance.
CHALLENGES IN CIRCULATING TUMOR CELL ANALYSIS
Many pitfalls need to be addressed before broader use of CTCs in clinical practice. CTC detection is challenging because of the rarity of CTCs among other blood cells; hence, different methods have been developed to enrich and isolate CTCs [3] . The CellSearch system -the only US Food and Drug Administration (FDA)-approved technology for CTC detection, uses the epithelial cell adhesion molecule (EpCAM) to positively enrich CTCs. However, this method is dependent on EpCAM expression on tumor cells. Alternative antigen-independent methods are in development, but clinical validity remains to be demonstrated [61] . Nevertheless, CTCs could be used in prospective clinical trials to select a high-risk population that may benefit from therapy intensification.
Circulating tumor cell characterization may be more promising than CTC detection to guide treatment-related decision. However, molecular analysis on CTCs must be interpreted with caution, considering the clonal heterogeneity of cancer, with evidence that no two cells are genetically identical [62] . Some studies revealed disagreements between mutations identified on CTCs and tumor tissue samples [50, 52, 63] . There are many unanswered questions; what is the clinical significance of mutations identified on CTCs, but not on tumor tissue? Do CTCs capture the molecular heterogeneity of metastatic disease? Can CTC models be derived only from patients with highly aggressive tumors? Can these models always capture treatment response?
CIRCULATING TUMOR DNA: A PROMISING BIOMARKER
DNA is released into circulation following cell-death processes. ctDNA fragments are typically the size of 160-180 bp, reflecting DNA degradation into nucleosomal units during the process of apoptosis [64] . Detection of ctDNA is challenging since it is found in low levels and has to be discriminated against nontumoral circulating free DNA (cfDNA). The feasibility of developing personalized ctDNA assay by identifying genomic alteration also present in the corresponding tumor tissue has been demonstrated in a few trials, the larger of which identified genetic alterations in various tumors, allowing ctDNA detection in 82% of the patients [65 & ]. In that study, ctDNA was detected at a high frequency in advanced pancreas, bladder, colon, melanoma, stomach, breast, liver, esophagus, and head and neck cancer, but was detected in less than 50% of patients with medulloblastoma, kidney, prostate, or thyroid cancer, and in less than 10% of patients with glioma. ctDNA was detected in only 55% of patients with localized cancer, but was overall more sensitive than CTCs.
Several small studies have demonstrated the association of ctDNA levels with tumor burden [4, 65 & ,66 & , [67] [68] [69] [70] [71] [72] , and adverse prognosis [67, [73] [74] [75] , in various cancer types. Preliminary data in breast, ovarian and colorectal cancer suggest that ctDNA could be used as a specific biomarker with better performance than classic blood tumor markers, with the potential to improve management of cancer patients (Fig. 1) [4, 69, 76, 77] . To that aim, ctDNA assays need to be integrated in prospective clinical trials to demonstrate clinical validity and utility in various cancer types.
CIRCULATING TUMOR DNA FOR GENOMIC PROFILING
The possibility to identify specific mutations on ctDNA has been demonstrated in several tumor types, with the most robust data in lung and CRC ( NRAS mutation Prediction of response to anti-EGFR treatment, Tracking emerging resistance mechanism [83, 85] BRAF Prediction of response to anti-EGFR treatment, Tracking emerging resistance mechanism [74] Esophagogastric APC methylation Prognostic evaluation [86] RASSF1A methylation Association with tumor burden [86] HER2 amplification Prediction of response to anti-HER2 treatment [87] Pancreas KRAS mutation Prognostic evaluation [88] Lung EGFR mutation Prediction of response to anti-EGFR treatment, Tracking emerging resistance mechanism [89] [90] [91] [92] [93] Prostate GSTP1 methylation Prognostic evaluation [94] Ovarian ERCC1 mutation Prediction of response to platinum-based chemotherapy, Prognostic evaluation [55] Melanoma BRAF mutation Prediction of response to anti-BRAF treatment [95, 96] Glioma MGMT methylation Prognostic evaluation [97] Gastro-Intestinal Stromal Tumor
KIT mutation Prediction of response to treatment with tyrosine kinases inhibitors [98] PDGFR mutation Prediction of response to treatment with tyrosine kinases inhibitors [98] Neuroblastoma ALK mutation Prediction of response to treatment with ALK inhibitors [99] the good specificity (88-93%) but lack of sensitivity (63-67%) of this approach [90, 100, 101] . However, the diagnostic performance of these assays is improving; for example, a ctDNA EGFR assay demonstrated 78% sensitivity within the EURTAC trial [102] . In the FASTACT2 trial randomizing patients to six cycles of gemcitabine/platinum with intercalated erlotinib versus placebo, the sensitivity of the ctDNA EGFR assay was 75%, and patients allocated to the erlotinib arm harboring EGFR mutation on cfDNA had longer PFS than the wildtype group [89] . The possibility to monitor the acquisition of mutations conferring resistance to targeted therapies was demonstrated in lung, colorectal, and breast cancer [78, 79, 83, 84, 91, 103] , also showing that 'resistant' clones are fading following therapy withdrawal, providing rationale for adaptive therapy strategies based on ctDNA molecular profile [83] . 104, 105] . Our laboratory demonstrated the feasibility of highcoverage NGS of a 50-gene panel in plasma samples from 17 mBC patients with high sensitivity (detection of mutations at allelic frequencies as low as 0.5%); when we compared tumor and plasma samples collected at the same time-point, the results were concordant in 76% of patients, whereas in 24%, they were discordant and provided complementary information [8 & ]. An interesting question is whether actionable mutations identified in plasma cfDNA are associated with treatment benefit, especially in cases when the mutation is not identified in matched metastatic biopsy. Another question is whether the detection of subclonal mutations with low allele fraction in plasma ctDNA is relevant for treatment selection. To address the above questions, plasma needs to be tested as an alternative tissue source to metastatic biopsies in molecular screening programs.
CONCLUSION AND FUTURE PERSPECTIVES
In summary, clinical applications for liquid biopsies are divided into two main categories. First, quantification of CTCs and ctDNA can provide prognostic information. Second, CTCs and ctDNA may allow accessible molecular profiling of the tumor. ctDNA could be used for the screening of mutations that predict response to therapy, and for real-time monitoring of clonal evolution to allow adaptive treatment strategy. In the presence of high tumor burden, comprehensive characterization of tumor DNA, RNA, and protein expression, along with functional analysis, could be performed on CTCs to optimize therapy selection. However, before application in clinical practice, these assays need to prove analytical and clinical validity, and then clinical utility. Prospective trials integrating these tools are needed to obtain such validation in the metastatic and early setting.
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